Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_1
2
33%
Ph not_applicable
1
17%
Ph phase_4
1
17%
Ph phase_3
2
33%

Phase Distribution

2

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (33.3%)
Phase 32 (33.3%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

NCT03704740
completedphase_1

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

NCT03893669
completedphase_1

Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers

NCT03826719
completedphase_4

Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis

NCT02686398
completednot_applicable

Training Study to Characterize Biomarkers to Flu Vaccines

NCT01771367
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03704740Phase 3

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Completed
NCT03893669Phase 1

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

Completed
NCT03826719Phase 1

Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers

Completed
NCT02686398Phase 4

Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis

Completed
NCT01771367Not Applicable

Training Study to Characterize Biomarkers to Flu Vaccines

Completed
NCT01310400Phase 3

Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6